Risk of Development Discontinuation Due to Competition and Loss of Market Advantage
First written in FY2022. 3 of 4 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 4 of 8 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If advances in the development or market launch of competing products result in changes to development plans, delays in launch timing, reductions in sales scale or other effects, milestone or royalty revenue may be affected.」
Continues to disclose the risk that competing technologies and products may affect development plans, launch timing, and milestone and royalty revenue. - FY2024RestatedAnnual report
「As a result of competition with these competitors, products developed by the Company through in-licensing or currently under development may lose their market advantage, potentially forcing the Company to discontinue R&D.」
Continues to disclose the risk of losing technological and market advantages and discontinuing development due to competition. - FY2023RestatedAnnual report
「As a result of competition with these competitors, products developed by the Company through in-licensing or currently under development may lose their market advantage, potentially forcing the Company to discontinue R&D.」
Continues to disclose the risk of losing market advantage and discontinuing development due to competition. - FY2022First statedAnnual report
「As a result of competition, products developed by the Company through in-licensing or currently under development may lose their market advantage, potentially forcing the Company to discontinue R&D.」
Recognises competition from domestic and overseas pharmaceutical companies, biotechnology companies and research institutions as a risk.